5 active not recruiting. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 5 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Shock: new trials by email Literature Review of Shock trials Research Report on Shock
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C Istaroxime, Placebo - Cardiogenic Shock | Phase 1 / Phase 2 | Active not recruiting | Windtree Therapeutics | 20 | 2024-06-01 | 2025-08-20 |
| Anakinra in Dengue With Hyperinflammation ( AnaDen ) Placebo, Anakinra - Dengue, Dengue With Warning Signs | Phase 2 | Active not recruiting | Oxford University Clinical Research Unit, Vietnam | 160 | 2023-01-02 | 2026-01-06 |
| Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock Tocilizumab, Dobutamine, NaCl 0.9% - Acute Myocardial Infarction, Cardiogenic Shock | Phase 2 | Active not recruiting | Copenhagen University Hospital, Rigshospitalet | 100 | 2022-03-13 | 2025-07-17 |
| Pentaglobin in CRE and PA Neutropenic Infections Pentaglobin - Septic Shock | Phase 2 | Active not recruiting | Gruppo Italiano Trapianto di Midollo Osseo | 120 | 2019-12-06 | 2025-01-06 |
| Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock nangibotide low dose, nangibotide high dose, placebo - Shock, Septic | Phase 2 | Active not recruiting | Inotrem | 355 | 2019-11-13 | 2023-04-11 |
Shock, Cardiogenic (2) · Shock, Septic (2) · Cytokine Release Syndrome (1) · Dengue (1) · Febrile Neutropenia (1) · Inflammation (1) · Macrophage Activation Syndrome (1) · Pseudomonas Infections (1) · ST Elevation Myocardial Infarction (1) · Severe Dengue (1)
Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Infections (3) · Inflammation (3) · Systemic Inflammatory Response Syndrome (3) · Cardiovascular Diseases (2) · Heart Diseases (2) · Infarction (2) · Ischemia (2) · Myocardial Infarction (2) · Myocardial Ischemia (2) · Necrosis (2) · Sepsis (2) · Vascular Diseases (2)
Dobutamine (1) · Interleukin 1 Receptor Antagonist Protein (1) · Istaroxime (1) · Lactic Acid (1) · Sodium Chloride (1) · nangibotide (1) · pentaglobulin (1) · tocilizumab (1)
Copenhagen University Hospital, Rigshospitalet (1) · Gruppo Italiano Trapianto di Midollo Osseo (1) · Inotrem (1) · Oxford University Clinical Research Unit, Vietnam (1) · Windtree Therapeutics (1)
Denmark (2) · Italy (2) · Argentina (1) · Belgium (1) · Finland (1) · France (1) · Ireland (1) · Israel (1) · Poland (1) · Spain (1) · United States (1) · Vietnam (1)
Fabio Ciceri (1) · Jean-Jacques Garaud, MD (1) · Martin Frydland, MD, PhD (1) · Sophie Yacoub (1) · Steven G Simonson, MD (1)
PMID 34233965, PMID 37269870, PMID 39931105
2018 (2)